{'fraction_non_alphanumeric': 0.036771300448430494, 'fraction_numerical': 0.014349775784753363, 'mean_word_length': 4.782383419689119, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A study on the regulation of growth hormone release from the pituitaries of rats in vitro.

In vitro studies have been performed to investigate the regulation of GH release from the pituitary of rats using the synthetic pentapeptides, Tyr-DTrp-Gly-Phe-Met-NH2 (DTrp2) or Tyr-Ala-DTrp-Phe-Met-NH2 (DTrp3), and the synthetic tetradecapeptide somatostatin (SRIF). DTrp2/3 act directly on the pituitary to specifically release GH and, thus, presumably mimic the action of the putative hypothalamic native GH-releasing hormone. The GH release induced by DTrp2/3 was dose related, occurred within 5 min, and was inhibited by small amounts (10–30 ng/ml incubation medium) of SRIF. Particular emphasis has been given to the possibility that GH from the pituitary of immature rats and mature rats may be influenced differently at the pituitary level. This latter conclusion was supported by the finding that the GH released by DTrp2/3 from the pituitary of the mature rat compared to that released in the immature rat was greater in magnitude but more easily inhibited by SRIF. Other differences included: 1) progressivel...